Elacestrant dihydrochloride

• CAT Number: I006453
• CAS Number: 1349723-93-8 (HCl)
• Molecular Formula: C30H40Cl2N2O2
• Molecular Weight: 531.56
• Purity: ≥95%
• Synonyms: RAD1901; RAD-1901; RAD 1901; RAD1901 HCl salt; Elacestrant dihydrochloride;(R)-6-(2-(ethyl(4-(2-(ethylamino)ethyl)benzyl)amino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol dihydrochloride
• Target: Estrogen Receptor/ERR
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4°C for short term or -20 °C for long term
• IUPAC Name: (6R)-6-[2-[ethyl-[[4-[2-(ethylamino)ethyl]phenyl]methyl]amino]-4-methoxyphenyl]-5,6,7,8-tetrahydronaphthalen-2-ol;dihydrochloride
• InChI: InChI=1S/C30H38N2O2.2ClH/c1-4-31-17-16-22-6-8-23(9-7-22)21-32(5-2)30-20-28(34-3)14-15-29(30)26-11-10-25-19-27(33)13-12-24(25)18-26;;/h6-9,12-15,19-20,26,31,33H,4-5,10-11,16-18,21H2,1-3H3;2*1H/t26-;;/m1../s1
• InChIKey: XGFHYCAZOCBCRQ-FBHGDYMESA-N
• SMILES: CCNCCC1=CC=C(C=C1)CN(CC)C2=C(C=CC(=C2)OC)[C@@H]3CCC4=C(C3)C=CC(=C4)O.Cl.Cl

Elacestrant dihydrochloride（Cat No.:I006453）is an oral selective estrogen receptor degrader (SERD) used in the treatment of estrogen receptor-positive (ER+) breast cancer, particularly in cases resistant to other therapies like tamoxifen or aromatase inhibitors. It works by binding to the estrogen receptor, promoting its degradation, and inhibiting the receptor’s ability to drive cancer cell growth. Elacestrant has shown promising results in clinical trials, offering a potential therapeutic option for patients with advanced or metastatic ER+ breast cancer who have developed resistance to standard endocrine therapies. Its safety and efficacy are continuously evaluated in ongoing studies.